New Efficacy And Safety Data Presented For Trajenta� (Linagliptin) In Asians With Type 2 Diabetes

New Phase III data presented at the American Diabetes Association 73rd Scientific Sessions� (ADA) showed linagliptin improved blood glucose control as monotherapy and in combination with metformin, in Asian people from China, Malaysia and the Philippines with Type 2 Diabetes. Boehringer Ingelheim and Eli Lilly and Company have presented results from two randomised Phase III clinical trials evaluating the efficacy and safety of linagliptin in Asians from China, Malaysia and the Philippines with Type 2 Diabetes (T2D)...

Source: http://feedproxy.google.com/~r/mnt/healthnews/~3/KkBopZp2T3g/262455.php

medical rehab sport